Acelyrin (SLRN) Stock Price, News & Analysis

Company Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Key Stats

• Today's Range: $4.29 to $4.76
• 50-Day Range: $4.31 to $6.48
• 52-Week Range: $3.36 to $8.89
• Volume: 495,028 shs
• Average Volume: 484,472 shs
• Market Capitalization: $471.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Moderate Buy

Acelyrin Stock Analysis - MarketRank™

Acelyrin scored higher than 69% of companies evaluated by MarketBeat, and ranked 338th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Acelyrin has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Acelyrin has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Acelyrin are expected to grow in the coming year, from ($2.57) to ($2.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acelyrin is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acelyrin is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acelyrin has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.33% of the float of Acelyrin has been sold short.

Short Interest Ratio / Days to Cover

Acelyrin has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Acelyrin has recently decreased by 8.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acelyrin does not currently pay a dividend.

Dividend Growth

Acelyrin does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.33% of the float of Acelyrin has been sold short.

Short Interest Ratio / Days to Cover

Acelyrin has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Acelyrin has recently decreased by 8.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.21

News Sentiment

Acelyrin has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Acelyrin this week, compared to 3 articles on an average week.

MarketBeat Follows

4 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acelyrin insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLRN Stock Analysis - Frequently Asked Questions

How have SLRN shares performed this year?

Acelyrin's stock was trading at $7.46 at the start of the year. Since then, SLRN shares have decreased by 37.0% and is now trading at $4.70.
View the best growth stocks for 2024 here.

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) announced its earnings results on Tuesday, August, 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.08.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an initial public offering on Friday, May 5th 2023. The company issued 30,000,000 shares at a price of $18.00 per share.

Who are Acelyrin's major shareholders?

Acelyrin's top institutional shareholders include Geode Capital Management LLC (1.65%), Jacobs Levy Equity Management Inc. (1.33%), State Street Corp (1.28%) and Ikarian Capital LLC (0.68%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg, Daniel J Becker and Ronald Oyston.
View institutional ownership trends.

How do I buy shares of Acelyrin?

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Acelyrin own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acelyrin investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLRN
• CUSIP: N/A
• CIK: 1962918
• Web: www.acelyrin.com
• Phone: 805-730-0360
• Fax: N/A
• Employees: 135
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.50
• High Stock Price Target: $20.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +144.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-381,640,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.12%
• Return on Assets: -39.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.15
• Quick Ratio: 7.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.27 per share
• Price / Book: 0.89

Miscellaneous

• Outstanding Shares: 100,330,000
• Free Float: 86,682,000
• Market Cap: $471.55 million
• Optionable: Optionable
• Beta: 1.98